

Compound: PF-07302048; Protocol: C4591001

Page 1 of 3

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1007 10071620; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 30DEC2020; Date of Last Dose: 20JAN2021

=====

| Demography | | | | |
|---------------|---------------------------|-------|-----------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2008 | 12 | White | Hispanic/Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 155.5 cm | 57.1 kg | 23.6 kg/m2 | 30DEC2020 (1) |

| Medical History | | | |
|----------------------------|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention deficit disorder | Attention deficit hyperactivity disorder | 2018 | Present |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 30DEC2020 (1) | 10:26 |
| 2 | BNT162b2 | 20JAN2021 (22) | 16:30 |

Compound: PF-07302048; Protocol: C4591001

Page 2 of 3

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1007 10071620; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 30DEC2020; Date of Last Dose: 20JAN2021

| Adverse Events | | | | | | | | | | | |
|----------------|------------|-----------------------|--|------------------------|------------|-----------------------|-----------|-----------------|----------------|-------------------|-----|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade | Action to Subject | SAE |
| 1 | GASTR | Abdominal pain | Abdominal pain | 21JAN2021 (23) | | 09FEB2021 (42) | | 20 | 2 | TC | N |
| 2 | GASTR | Abdominal pain | Functional Abdominal Pain | 28FEB2021 (61) | | ONGOING | | | 3 | TC | Y |
| 3 | GASTR | Constipation | Constipation | 28FEB2021 (61) | | ONGOING | | | 3 | TC | Y |
| 4 | SKIN | Dermatitis contact | contact dermatitis bilateral arms | 12FEB2021 (45) | | ONGOING | | | 1 | TC | N |
| 5 | GASTR | Gastritis | Gastritis | 30JAN2021 (32) | | ONGOING | | | 2 | TC | N |
| 6 | NERV | Neuralgia | generalized Functional neurologic pain | 21JAN2021 (23) | | ONGOING | | | 2 | TC | Y |
| 7 | INFEC | Vulval abscess | Vulvar boil | 24JAN2021 (26) | | 26JAN2021 (28) | | 3 | 1 | TC | N |

| Adverse Events | | | | | |
|----------------|----------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | Resolved (09FEB2021) | Study Treatment | 2 | 2 | N |
| 2 | Yes | NOT RELATED/OTHER: no organic cause; no known precipitating factors | 2 | 40 | Y |
| 3 | Yes | NOT RELATED/OTHER: no organic cause identified | 2 | 40 | Y |
| 4 | Yes | NOT RELATED/OTHER: suspected reaction to tape | 2 | 24 | N |
| 5 | Yes | NOT RELATED/CONCOMITANT DRUG TREATMENT | 2 | 11 | N |
| 6 | Yes | NOT RELATED/OTHER: unspecified | 2 | 2 | Y |
| 7 | Resolved (26JAN2021) | NOT RELATED/OTHER: Presumed staph infection | 2 | 5 | N |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1007 10071620; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 30DEC2020; Date of Last Dose: 20JAN2021

=====

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 30DEC2020 | |
| Completed | VACCINATION | 18FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1001 10011125; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04AUG2020; Date of Last Dose: 04AUG2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1997 | 23 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 156.2 cm | 46.8 kg | 19.2 kg/m2 | 04AUG2020 (1) |

| Medical History |
|--------------------|
| No Medical History |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 04AUG2020 (1) | 14:30 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1001 10011125; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04AUG2020; Date of Last Dose: 04AUG2020

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Disorientation | disorientation | 08AUG2020 (5) | 13:00 | 09AUG2020 (6) | | 2 |
| 2 | NERV | Dizziness | dizziness | 04AUG2020 (1) | 14:00 | 04AUG2020 (1) | 14:10 | 1 |
| 3 | NERV | Migraine | migraine headache | 05AUG2020 (2) | | 09AUG2020 (6) | | 5 |
| 4 | MUSC | Myalgia | diffuse myalgias | 06AUG2020 (3) | | 07AUG2020 (4) | | 2 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|-----------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | N | N | Resolved (09AUG2020) | NOT RELATED/OTHER: afternoon heat | 1 | 5 | N |
| 2 | 1 | N | N | Resolved (04AUG2020) | Study Treatment | 1 | 1 | N |
| 3 | 3 | N | N | Resolved (09AUG2020) | Study Treatment | 1 | 2 | N |
| 4 | 3 | N | N | Resolved (07AUG2020) | Study Treatment | 1 | 3 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1001 10011125; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04AUG2020; Date of Last Dose: 04AUG2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 04AUG2020 | |
| Withdrawn | VACCINATION | 09SEP2020 | WITHDRAWAL BY SUBJECT |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| Withdrawn | FOLLOW-UP | 09SEP2020 | WITHDRAWAL BY SUBJECT |

Compound: PF-07302048; Protocol: C4591001

Page 4 of 55

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|---------------------------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2007 | 13 | Black or African American | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 172.72 cm | 67.27 kg | 22.5 kg/m2 | 16DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention Deficit Hyperactivity Disorder | Attention deficit hyperactivity disorder | 2010 | Present |
| Separation Anxiety Disorder | Separation anxiety disorder | 2010 | Present |
| Disruptive Mood Dysregulation Disorder | Disruptive mood dysregulation disorder | 2012 | Present |
| Asthma | Asthma | 2013 | Present |
| Anxiety | Anxiety | 2014 | Present |
| Depression | Depression | 2014 | Present |
| Recurring Insomnia | Insomnia | 2014 | Present |
| Recurring Nightmares | Nightmare | 2015 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Safety-Related Subject Withdrawal
Unique Subject ID: C4591001 1006 10061272; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

| Medical History | | | |
|--------------------------------|--------------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Post Traumatic Stress Disorder | Post-traumatic stress disorder | 06NOV2015 | Present |
| Aggressive Behaviors | Aggression | 2017 | Past |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 16DEC2020 (1) | 12:07 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Anxiety | Worsening of anxiety | 23DEC2020 (8) | | 18JAN2021 (34) | | 27 |
| 2 | INJ&P | Contusion | Contusion left elbow | 05FEB2021 (52) | | ONGOING | | |
| 3 | PSYCH | Depression | Worsening of Depression | 23DEC2020 (8) | | 18JAN2021 (34) | | 27 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|--------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC/TCN/P | Y | Resolved (18JAN2021) | NOT RELATED/OTHER: Stress | 1 | 8 | Y |
| 2 | 1 | N | N | Yes | NOT RELATED/OTHER: Fall on ice | 1 | 52 | N |
| 3 | 3 | TC/TCN/P | Y | Resolved (18JAN2021) | NOT RELATED/OTHER: Stress | 1 | 8 | Y |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Safety-Related Subject Withdrawal
Unique Subject ID: C4591001 1006 10061272; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 16DEC2020 | |
| Withdrawn | VACCINATION | 06JAN2021 | ADVERSE EVENT |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 7 of 55

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

Narrative Comment

Subject C4591001 1006 10061272, a 13-year-old black or African American female with a pertinent medical history of attention deficit hyperactivity disorder and separation anxiety disorder (both since 2010); disruptive mood dysregulation disorder (since 2012); anxiety, depression, and recurring insomnia (all since 2014); recurring nightmares (since 2015); posttraumatic stress disorder (since 06 Nov 2015); and aggression (in 2017 with 4 days' hospitalization), received Dose 1 on 16 Dec 2020. The family medical history was pertinent for posttraumatic stress disorder, borderline personality disorder (b) (6) and drug addiction (b) (6). The subject experienced worsening of anxiety and worsening of depression on 23 Dec 2020, 7 days after receiving Dose 1.

Concomitant medications included salbutamol and fluticasone propionate (both since 2013) and montelukast sodium (from 2013 to 30 Dec 2020) for asthma; and duloxetine hydrochloride (from 2019 to 30 Dec 2020) and citalopram hydrobromide (from Oct 2020 to 30 Dec 2020), both for depression.

The subject, with an ongoing medical history of anxiety and depression, which were stable at Visit 1, experienced worsening of anxiety and depression after Visit 1 on 23 Dec 2020 (Day 8) and was hospitalized for 14 days. During hospitalization, the subject was seen by a physician and was treated with aripiprazole 1 mg and venlafaxine 150 mg per day (starting on 30 Dec 2020) and the physician recommended admission to an inpatient residential treatment/psychiatric facility. On 05 Jan 2021 (Day 21), the subject was admitted to an inpatient residential treatment/psychiatric facility for medical management and stabilization. The subject was not tested for COVID-19. During a scheduled visit, the subject and her guardian stated that the subject's mental health had stabilized, and she was treated with trazodone 50 mg every night (from 06 Jan 2021) for her history of recurring insomnia. On 18 Jan 2021 (Day 34), the worsening of anxiety and worsening of depression resolved and the subject was discharged from the hospital on the same day.

The subject was discontinued from the study intervention on 06 Jan 2021 because of the worsening of anxiety and depression and remains in the study to be evaluated for safety, immunogenicity, and efficacy.

In the opinion of the investigator, there was no reasonable possibility that the worsening of anxiety and worsening of depression were related to the study intervention, concomitant medications, or clinical trial procedures, but rather they were related to stress. Pfizer did not assess the worsening of anxiety and worsening of depression as related to the study intervention, concomitant medications, or clinical trial procedures.

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1007 10071500; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 03DEC2020; Date of Last Dose: 22DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 15 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 163.3 cm | 51.3 kg | 19.2 kg/m2 | 03DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention deficit-hyperactivity disorder | Attention deficit hyperactivity disorder | 2011 | Present |
| Seasonal allergy | Seasonal allergy | 2014 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1007 10071500; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 03DEC2020; Date of Last Dose: 22DEC2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 03DEC2020 (1) | 16:54 |
| 2 | BNT162b2 | 22DEC2020 (20) | 10:26 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Sleep terror | Night Terror | 23DEC2020 (21) | | 23DEC2020 (21) | | 1 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|---------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | N | N | Resolved (23DEC2020) | NOT RELATED/OTHER: stress | 2 | 2 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1007 10071500; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 03DEC2020; Date of Last Dose: 22DEC2020

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 03DEC2020 | |
| Completed | VACCINATION | 21JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1039 10391250; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 28DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 167.5 cm | 60.6 kg | 21.6 kg/m2 | 04DEC2020 (1) |

| Medical History | | | |
|------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| benign cyst right foot | Cyst | 2015 | Past |
| menarche | Menarche | 2018 | Present |
| TIC syndrome | Tic | 2019 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1039 10391250; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 28DEC2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 04DEC2020 (1) | 09:34 |
| 2 | BNT162b2 | 28DEC2020 (25) | 08:28 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|------------------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Tic | exacerbation of tic disorder | 09JAN2021 (37) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|-----------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | N | N | Yes | NOT RELATED/OTHER: stress in life | 2 | 13 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1039 10391250; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 28DEC2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 04DEC2020 | |
| Completed | VACCINATION | 27JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 14 of 55

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 15 | Asian | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 177.7 cm | 65.5 kg | 20.7 kg/m2 | 11JAN2021 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| asthma | Asthma | 2006 | Past |
| glasses user | Corrective lens user | 2012 | Present |
| seasonal allergic rhinitis | Seasonal allergy | 2016 | Present |
| anxiety | Anxiety | 2018 | Present |
| attention deficit hyperactivity disorder | Attention deficit hyperactivity disorder | 2018 | Present |
| Depression | Depression | 2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 15 of 55

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 11JAN2021 (1) | 12:50 |
| 2 | BNT162b2 | 01FEB2021 (22) | 08:31 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Depression Exacerbation | 26JAN2021 (16) | | 30JAN2021 (20) | | 5 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|---------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC/TCN | Y | Resolved (30JAN2021) | NOT RELATED/OTHER: Stress | 1 | 16 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 11JAN2021 | |
| Completed | VACCINATION | 04MAR2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 17 of 55

Reason(s) for Narrative: Adverse Events With Numerical Imbalance Between Vaccine Groups

Unique Subject ID: C4591001 1044 10441373; Country: USA

Vaccine Group (as Administered): Placebo

Date of First Dose: 12JAN2021; Date of Last Dose: 04FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|----------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 156.2 cm | 43.9 kg | 18 kg/m2 | 12JAN2021 (1) |

| Medical History | | | |
|-------------------------------|---------------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| GERD | Gastroesophageal reflux disease | 2006 | Present |
| Allergic Rhinitis | Rhinitis allergic | 2011 | Present |
| anxiety | Anxiety | 2018 | Present |
| Obsessive-compulsive disorder | Obsessive-compulsive disorder | 2020 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 18 of 55

Reason(s) for Narrative: Adverse Events With Numerical Imbalance Between Vaccine Groups

Unique Subject ID: C4591001 1044 10441373; Country: USA

Vaccine Group (as Administered): Placebo

Date of First Dose: 12JAN2021; Date of Last Dose: 04FEB2021

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 12JAN2021 (1) | 10:33 |
| 2 | Placebo | 04FEB2021 (24) | 10:04 |

| Adverse Events | | | | | | | | | |
|----------------|------------|-----------------------|----------------------|------------------------|------------|-----------------------|-----------|-----------------|----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade |
| 1 | PSYCH | Anxiety | Worsening of Anxiety | 05MAR2021 (53) | | ONGOING | | | 2 |
| 2 | SKIN | Urticaria | hives forehead | 12JAN2021 (1) | 11:29 | 12JAN2021 (1) | | 1 | 1 |

| Adverse Events | | | | | | | |
|----------------|-------------------|-----|----------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | TC | N | Yes | NOT RELATED/OTHER: medication dosage adjustment | 2 | 30 | N |
| 2 | N | N | Resolved (12JAN2021) | Study Treatment | 1 | 1 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Page 19 of 55

Reason(s) for Narrative: Adverse Events With Numerical Imbalance Between Vaccine Groups

Unique Subject ID: C4591001 1044 10441373; Country: USA

Vaccine Group (as Administered): Placebo

Date of First Dose: 12JAN2021; Date of Last Dose: 04FEB2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 12JAN2021 | |
| Completed | VACCINATION | 09MAR2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 20 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1077 10771278; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 04DEC2020; Date of Last Dose: 23DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2007 | 13 | White | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 165.1 cm | 47.09 kg | 17.2 kg/m2 | 04DEC2020 (1) |

| Medical History |
|--------------------|
| No Medical History |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 04DEC2020 (1) | 09:45 |
| 2 | BNT162b2 | 23DEC2020 (20) | 10:09 |

Compound: PF-07302048; Protocol: C4591001

Page 21 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1077 10771278; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 04DEC2020; Date of Last Dose: 23DEC2020

| Adverse Events | | | | | | | |
|----------------|------------|-------------------------|-------------------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | GASTR | Diarrhoea | DIARRHEA | 23DEC2020 (20) | 12:30 | 24DEC2020 (21) | 12:01 |
| 2 | PSYCH | Disorientation | DISORIENTATION | 23DEC2020 (20) | 19:01 | 23DEC2020 (20) | 20:00 |
| 3 | GENRL | Fatigue | FATIGUE | 23DEC2020 (20) | 14:00 | 24DEC2020 (21) | |
| 4 | GENRL | Injection site pain | RIGHT ARM INJECTION SITE PAIN | 23DEC2020 (20) | 12:00 | 24DEC2020 (21) | 22:00 |
| 5 | GENRL | Injection site swelling | INJECTION SITE SWELLING | 23DEC2020 (20) | 12:00 | 24DEC2020 (21) | 21:00 |
| 6 | GENRL | Pyrexia | FEVER | 23DEC2020 (20) | 19:01 | 24DEC2020 (21) | 12:00 |
| 7 | GASTR | Vomiting | VOMITING | 23DEC2020 (20) | 20:00 | 23DEC2020 (20) | 21:00 |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|----------------------|-----------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | 2 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 2 | 1 | 2 | N | N | Resolved (23DEC2020) | Study Treatment | 2 | 1 | N |
| 3 | 2 | 2 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 4 | 2 | 1 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 5 | 2 | 2 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 6 | 2 | 3 | TC | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 7 | 1 | 1 | N | N | Resolved (23DEC2020) | Study Treatment | 2 | 1 | N |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1077 10771278; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 23DEC2020

=====

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 04DEC2020 | |
| Completed | VACCINATION | 22JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1095 10951308; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 17NOV2020; Date of Last Dose: 10DEC2020

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2003 | 17 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|--------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 173 cm | 62 kg | 20.7 kg/m2 | 17NOV2020 (1) |

| Medical History | | | |
|-------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Depression | Depression | DEC2016 | Present |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 17NOV2020 (1) | 15:49 |
| 2 | BNT162b2 | 10DEC2020 (24) | 16:26 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1095 10951308; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 17NOV2020; Date of Last Dose: 10DEC2020

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | worsening of depression | DEC2020 () | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | TC | N | Yes | NOT RELATED/OTHER: history of depression | | | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1095 10951308; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 17NOV2020; Date of Last Dose: 10DEC2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 17NOV2020 | |
| Completed | VACCINATION | 14JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1095 10951310; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 19NOV2020; Date of Last Dose: 15DEC2020

| Demography | | | | |
|---------------|---------------------------|-------|-----------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2003 | 17 | White | Hispanic/Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 172.5 cm | 62.2 kg | 20.9 kg/m2 | 19NOV2020 (1) |

| Medical History |
|--------------------|
| No Medical History |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 19NOV2020 (1) | 10:29 |
| 2 | BNT162b2 | 15DEC2020 (27) | 10:06 |

Compound: PF-07302048; Protocol: C4591001

Page 27 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1095 10951310; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 19NOV2020; Date of Last Dose: 15DEC2020

=====

| Adverse Events | | | | | | | |
|----------------|------------|--|--------------------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Attention deficit hyperactivity disorder | ADHD diagnosed by Psychiatrist | 25JAN2021 (68) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|-------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | TC | N | Yes | NOT RELATED/OTHER: ADHD | 2 | 42 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1095 10951310; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 19NOV2020; Date of Last Dose: 15DEC2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 19NOV2020 | |
| Completed | VACCINATION | 12FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1123 11231442; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 04JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2008 | 12 | White | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 164 cm | 86.5 kg | 32.2 kg/m2 | 09DEC2020 (1) |

| Medical History | | | |
|------------------------|---------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Chronic strep throat | Pharyngitis streptococcal | 2016 | Past |
| Adenoidectomy | Adenoidectomy | 2017 | Past |
| Intermittent headaches | Headache | 2017 | Present |
| Obesity | Obesity | 2017 | Present |
| Tonsillectomy | Tonsillectomy | 2017 | Past |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1123 11231442; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 04JAN2021

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 09DEC2020 (1) | 12:33 |
| 2 | Placebo | 04JAN2021 (27) | 13:48 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Depression | Depression | 23DEC2020 (15) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|----------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 2 | TC | N | Yes | NOT RELATED/OTHER: unknown | 1 | 15 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1123 11231442; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 04JAN2021

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 09DEC2020 | |
| Completed | VACCINATION | 01FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 32 of 55

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 162.5 cm | 50.7 kg | 19.2 kg/m2 | 28DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Seasonal allergies | Seasonal allergy | 2008 | Present |
| Attention deficit hyperactive disorder | Attention deficit hyperactivity disorder | 2013 | Present |
| Migraines | Migraine | 2015 | Present |
| Anxiety | Anxiety | OCT2018 | Present |
| Depression | Depression | OCT2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 33 of 55

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 28DEC2020 (1) | 16:52 |
| 2 | BNT162b2 | 18JAN2021 (22) | 11:50 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Worsening of Depression | 19JAN2021 (23) | | 23JAN2021 (27) | | 5 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|----------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | TC | Y | Resolved (23JAN2021) | NOT RELATED/OTHER: unknown | 2 | 2 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 28DEC2020 | |
| Completed | VACCINATION | 16FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 35 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1126 11261205; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11NOV2020; Date of Last Dose: 02DEC2020

| Demography | | | | |
|---------------|---------------------------|---------------------------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2004 | 16 | Black or African American | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 180.3 cm | 65.7 kg | 20.2 kg/m2 | 11NOV2020 (1) |

| Medical History |
|--------------------|
| No Medical History |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 11NOV2020 (1) | 13:27 |
| 2 | BNT162b2 | 02DEC2020 (22) | 12:00 |

Compound: PF-07302048; Protocol: C4591001

Page 36 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1126 11261205; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11NOV2020; Date of Last Dose: 02DEC2020

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|--------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | METAB | Decreased appetite | Decreased appetite | 23NOV2020 (13) | | ONGOING | | |
| 2 | PSYCH | Depressed mood | Depressed mood | 23NOV2020 (13) | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | N | N | Yes | NOT RELATED/OTHER: COVID 19 Pandemic life stressors | 1 | 13 | N |
| 2 | 1 | N | N | Yes | NOT RELATED/OTHER: COVID 19 Pandemic life stressors | 1 | 13 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1126 11261205; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 11NOV2020; Date of Last Dose: 02DEC2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 11NOV2020 | |
| Completed | VACCINATION | 06JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 38 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1141 11411010; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 31JUL2020; Date of Last Dose: 28JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1996 | 24 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|----------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 167.5 cm | 64.4 kg | 23 kg/m2 | 31JUL2020 (1) |

| Medical History | | | |
|-----------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Intermittent Insomnia | Insomnia | 2018 | Present |
| Menstrual Cramps | Dysmenorrhoea | 2019 | Present |

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 31JUL2020 (1) | 15:21 |

Compound: PF-07302048; Protocol: C4591001

Page 39 of 55

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1141 11411010; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 31JUL2020; Date of Last Dose: 28JAN2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 2 | Placebo | 01SEP2020 (33) | 12:47 |
| 3 | BNT162b2 | 05JAN2021 (159) | 13:56 |
| 4 | BNT162b2 | 28JAN2021 (182) | 15:06 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Anxiety | Anxiousness | 14SEP2020 (46) | | 15DEC2020 (138) | 12:00 | 93 |
| 2 | PSYCH | Depressed mood | Low Mood | 14SEP2020 (46) | | 15DEC2020 (138) | | 93 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|----------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | TCN | N | Resolved (15DEC2020) | NOT RELATED/OTHER: Social Stress | 2 | 14 | N |
| 2 | 2 | TCN | N | Resolved (15DEC2020) | NOT RELATED/OTHER: Social Stress | 2 | 14 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1141 11411010; Country: USA
Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)
Date of First Dose: 31JUL2020; Date of Last Dose: 28JAN2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 31JUL2020 | |
| Completed | VACCINATION | 01OCT2020 | |
| Completed | REPEAT SCREENING 1 | 05JAN2021 | |
| Completed | OPEN LABEL TREATMENT | 09MAR2021 | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1141 11411029; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04AUG2020; Date of Last Dose: 26AUG2020

=====

Page 41 of 55

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1995 | 25 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|--------|----------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 162 cm | 84 kg | 32 kg/m2 | 04AUG2020 (1) |

| Medical History | | | |
|---|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| nearsighted | Myopia | 2005 | Present |
| menstrual cramps | Dysmenorrhoea | 2007 | Present |
| acne | Acne | 2009 | Present |
| keratosis pilaris bilateral arms and legs | Keratosis pilaris | 2009 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1141 11411029; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04AUG2020; Date of Last Dose: 26AUG2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 04AUG2020 (1) | 17:11 |
| 2 | BNT162b2 | 26AUG2020 (23) | 16:02 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Anxiety | Anxiety Flare up | 18SEP2020 (46) | 08:00 | ONGOING | |
| 2 | MUSC | Arthralgia | Arthralgias | 17SEP2020 (45) | 08:00 | 28SEP2020 (56) | 08:00 |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|----------------------|-----------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | TC/TCN | N | Yes | Study Treatment | 2 | 24 | N |
| 2 | 12 | 2 | TC/TCN | N | Resolved (28SEP2020) | Study Treatment | 2 | 23 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1141 11411029; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04AUG2020; Date of Last Dose: 26AUG2020

| Nonstudy Vaccines | | |
|-------------------|-------------------------|------------|
| Investigator Text | WHO Drug Preferred Term | Start Date |
| Influenza Vaccine | INFLUENZA VACCINE | NOV2020 |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 04AUG2020 | |
| Completed | VACCINATION | 23SEP2020 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1147 11471262; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 12DEC2020; Date of Last Dose: 04JAN2021

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 165.2 cm | 65.15 kg | 23.9 kg/m2 | 12DEC2020 (1) |

| Medical History | | | |
|------------------------------|------------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Generalized anxiety disorder | Generalised anxiety disorder | 2020 | Present |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 12DEC2020 (1) | 09:09 |
| 2 | BNT162b2 | 04JAN2021 (24) | 10:25 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1147 11471262; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 12DEC2020; Date of Last Dose: 04JAN2021

| Adverse Events | | | | | | | | |
|----------------|------------|------------------------------|--|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Generalised anxiety disorder | Generalized anxiety disorder (worsening) | 25JAN2021 (45) | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | TC | N | Yes | NOT RELATED/OTHER: Worsening condition | 2 | 22 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines | | |
|-------------------|-------------------------|------------|
| Investigator Text | WHO Drug Preferred Term | Start Date |
| Influenza vaccine | INFLUENZA VACCINE | 23NOV2020 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1147 11471262; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 12DEC2020; Date of Last Dose: 04JAN2021

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 01DEC2020 | |
| Completed | VACCINATION | 06FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1150 11501193; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 10DEC2020; Date of Last Dose: 31DEC2020

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 163.83 cm | 50.27 kg | 18.7 kg/m2 | 10DEC2020 (1) |

| Medical History | | | |
|----------------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Sun butter Allergy- Food Allergy | Food allergy | 2016 | Present |
| Sesame Seed Allergy | Food allergy | 2016 | Present |
| Seasonal Allergies | Seasonal allergy | 2016 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1150 11501193; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 10DEC2020; Date of Last Dose: 31DEC2020

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 10DEC2020 (1) | 15:02 |
| 2 | Placebo | 31DEC2020 (22) | 10:25 |

| Adverse Events | | | | | | | |
|----------------|------------|--|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Attention deficit hyperactivity disorder | ADHD | DEC2020 () | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|-------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | N | N | Yes | NOT RELATED/OTHER: ADHD | | | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1150 11501193; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 10DEC2020; Date of Last Dose: 31DEC2020

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 10DEC2020 | |
| Completed | VACCINATION | 01FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1152 11521654; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 29DEC2020

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 160.66 cm | 80.45 kg | 31.1 kg/m2 | 09DEC2020 (1) |

| Medical History | | | |
|--|---|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| DEPRESSION | Depression | 2010 | Present |
| foreign body right ear lobe | Foreign body in ear | 2011 | Past |
| surgical removal foreign object right ear lobe | Removal of foreign body from external ear | 2011 | Past |
| astigmatism | Astigmatism | 2015 | Present |
| seasonal allergies | Seasonal allergy | 2015 | Present |
| frequent headaches | Headache | 2018 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1152 11521654; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 29DEC2020

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 09DEC2020 (1) | 11:45 |
| 2 | Placebo | 29DEC2020 (21) | 10:09 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|---------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Worsened Depression | 26DEC2020 (18) | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | TC | N | Yes | NOT RELATED/OTHER: Pre-existing condition | 1 | 18 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1152 11521654; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 29DEC2020

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 09DEC2020 | |
| Completed | VACCINATION | 27JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1270 12701236; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 06JAN2021; Date of Last Dose: 25JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 164.8 cm | 71.6 kg | 26.4 kg/m2 | 06JAN2021 (1) |

| Medical History | | | |
|-----------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| LEARNING DIFFICULTIES | Learning disorder | 08AUG2017 | Present |

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 06JAN2021 (1) | 15:18 |
| 2 | Placebo | 25JAN2021 (20) | 14:29 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1270 12701236; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 06JAN2021; Date of Last Dose: 25JAN2021

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Anxiety | Anxiety | 11JAN2021 (6) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|--------------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | N | N | Yes | NOT RELATED/OTHER: Social Situations | 1 | 6 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1270 12701236; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 06JAN2021; Date of Last Dose: 25JAN2021

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 06JAN2021 | |
| Completed | VACCINATION | 23FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 1 of 40

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|---------------------------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2007 | 13 | Black or African American | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 172.72 cm | 67.27 kg | 22.5 kg/m2 | 16DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention Deficit Hyperactivity Disorder | Attention deficit hyperactivity disorder | 2010 | Present |
| Separation Anxiety Disorder | Separation anxiety disorder | 2010 | Present |
| Disruptive Mood Dysregulation Disorder | Disruptive mood dysregulation disorder | 2012 | Present |
| Asthma | Asthma | 2013 | Present |
| Anxiety | Anxiety | 2014 | Present |
| Depression | Depression | 2014 | Present |
| Recurring Insomnia | Insomnia | 2014 | Present |
| Recurring Nightmares | Nightmare | 2015 | Present |
| Post Traumatic Stress Disorder | Post-traumatic stress disorder | 06NOV2015 | Present |
| Aggressive Behaviors | Aggression | 2017 | Past |

Compound: PF-07302048; Protocol: C4591001

Page 2 of 40

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 16DEC2020 (1) | 12:07 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Anxiety | Worsening of anxiety | 23DEC2020 (8) | | 18JAN2021 (34) | | 27 |
| 2 | INJ&P | Contusion | Contusion left elbow | 05FEB2021 (52) | | ONGOING | | |
| 3 | PSYCH | Depression | Worsening of Depression | 23DEC2020 (8) | | 18JAN2021 (34) | | 27 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|--------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC/TCN/P | Y | Resolved (18JAN2021) | NOT RELATED/OTHER: Stress | 1 | 8 | Y |
| 2 | 1 | N | N | Yes | NOT RELATED/OTHER: Fall on ice | 1 | 52 | N |
| 3 | 3 | TC/TCN/P | Y | Resolved (18JAN2021) | NOT RELATED/OTHER: Stress | 1 | 8 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Safety-Related Subject Withdrawal
Unique Subject ID: C4591001 1006 10061272; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 16DEC2020 | |
| Withdrawn | VACCINATION | 06JAN2021 | ADVERSE EVENT |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 4 of 40

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

Narrative Comment

Subject C4591001 1006 10061272, a 13-year-old black or African American female with a pertinent medical history of attention deficit hyperactivity disorder and separation anxiety disorder (both since 2010); disruptive mood dysregulation disorder (since 2012); anxiety, depression, and recurring insomnia (all since 2014); recurring nightmares (since 2015); posttraumatic stress disorder (since 06 Nov 2015); and aggression (in 2017 with 4 days' hospitalization), received Dose 1 on 16 Dec 2020. The family medical history was pertinent for posttraumatic stress disorder, borderline personality disorder (b) (6) and drug addiction (b) (6). The subject experienced worsening of anxiety and worsening of depression on 23 Dec 2020, 7 days after receiving Dose 1.

Concomitant medications included salbutamol and fluticasone propionate (both since 2013) and montelukast sodium (from 2013 to 30 Dec 2020) for asthma; and duloxetine hydrochloride (from 2019 to 30 Dec 2020) and citalopram hydrobromide (from Oct 2020 to 30 Dec 2020), both for depression.

The subject, with an ongoing medical history of anxiety and depression, which were stable at Visit 1, experienced worsening of anxiety and depression after Visit 1 on 23 Dec 2020 (Day 8) and was hospitalized for 14 days. During hospitalization, the subject was seen by a physician and was treated with aripiprazole 1 mg and venlafaxine 150 mg per day (starting on 30 Dec 2020) and the physician recommended admission to an inpatient residential treatment/psychiatric facility. On 05 Jan 2021 (Day 21), the subject was admitted to an inpatient residential treatment/psychiatric facility for medical management and stabilization. The subject was not tested for COVID-19. During a scheduled visit, the subject and her guardian stated that the subject's mental health had stabilized, and she was treated with trazodone 50 mg every night (from 06 Jan 2021) for her history of recurring insomnia. On 18 Jan 2021 (Day 34), the worsening of anxiety and worsening of depression resolved and the subject was discharged from the hospital on the same day.

The subject was discontinued from the study intervention on 06 Jan 2021 because of the worsening of anxiety and depression and remains in the study to be evaluated for safety, immunogenicity, and efficacy.

In the opinion of the investigator, there was no reasonable possibility that the worsening of anxiety and worsening of depression were related to the study intervention, concomitant medications, or clinical trial procedures, but rather they were related to stress. Pfizer did not assess the worsening of anxiety and worsening of depression as related to the study intervention, concomitant medications, or clinical trial procedures.

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1007 10071500; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 03DEC2020; Date of Last Dose: 22DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 15 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 163.3 cm | 51.3 kg | 19.2 kg/m2 | 03DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention deficit-hyperactivity disorder | Attention deficit hyperactivity disorder | 2011 | Present |
| Seasonal allergy | Seasonal allergy | 2014 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1007 10071500; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 03DEC2020; Date of Last Dose: 22DEC2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 03DEC2020 (1) | 16:54 |
| 2 | BNT162b2 | 22DEC2020 (20) | 10:26 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Sleep terror | Night Terror | 23DEC2020 (21) | | 23DEC2020 (21) | | 1 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|---------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | N | N | Resolved (23DEC2020) | NOT RELATED/OTHER: stress | 2 | 2 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1007 10071500; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 03DEC2020; Date of Last Dose: 22DEC2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 03DEC2020 | |
| Completed | VACCINATION | 21JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1039 10391250; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 28DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 167.5 cm | 60.6 kg | 21.6 kg/m2 | 04DEC2020 (1) |

| Medical History | | | |
|------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| benign cyst right foot | Cyst | 2015 | Past |
| menarche | Menarche | 2018 | Present |
| TIC syndrome | Tic | 2019 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1039 10391250; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 28DEC2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 04DEC2020 (1) | 09:34 |
| 2 | BNT162b2 | 28DEC2020 (25) | 08:28 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|------------------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Tic | exacerbation of tic disorder | 09JAN2021 (37) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|-----------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | N | N | Yes | NOT RELATED/OTHER: stress in life | 2 | 13 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1039 10391250; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 28DEC2020

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 04DEC2020 | |
| Completed | VACCINATION | 27JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 11 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 15 | Asian | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 177.7 cm | 65.5 kg | 20.7 kg/m2 | 11JAN2021 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| asthma | Asthma | 2006 | Past |
| glasses user | Corrective lens user | 2012 | Present |
| seasonal allergic rhinitis | Seasonal allergy | 2016 | Present |
| anxiety | Anxiety | 2018 | Present |
| attention deficit hyperactivity disorder | Attention deficit hyperactivity disorder | 2018 | Present |
| Depression | Depression | 2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 12 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 11JAN2021 (1) | 12:50 |
| 2 | BNT162b2 | 01FEB2021 (22) | 08:31 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Depression Exacerbation | 26JAN2021 (16) | | 30JAN2021 (20) | | 5 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|---------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC/TCN | Y | Resolved (30JAN2021) | NOT RELATED/OTHER: Stress | 1 | 16 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Page 13 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 11JAN2021 | |
| Completed | VACCINATION | 04MAR2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 14 of 40

Reason(s) for Narrative: Adverse Events With Numerical Imbalance Between Vaccine Groups

Unique Subject ID: C4591001 1044 10441373; Country: USA

Vaccine Group (as Administered): Placebo

Date of First Dose: 12JAN2021; Date of Last Dose: 04FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|----------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 156.2 cm | 43.9 kg | 18 kg/m2 | 12JAN2021 (1) |

| Medical History | | | |
|-------------------------------|---------------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| GERD | Gastroesophageal reflux disease | 2006 | Present |
| Allergic Rhinitis | Rhinitis allergic | 2011 | Present |
| anxiety | Anxiety | 2018 | Present |
| Obsessive-compulsive disorder | Obsessive-compulsive disorder | 2020 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 15 of 40

Reason(s) for Narrative: Adverse Events With Numerical Imbalance Between Vaccine Groups

Unique Subject ID: C4591001 1044 10441373; Country: USA

Vaccine Group (as Administered): Placebo

Date of First Dose: 12JAN2021; Date of Last Dose: 04FEB2021

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 12JAN2021 (1) | 10:33 |
| 2 | Placebo | 04FEB2021 (24) | 10:04 |

| Adverse Events | | | | | | | | | |
|----------------|------------|-----------------------|----------------------|------------------------|------------|-----------------------|-----------|-----------------|----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade |
| 1 | PSYCH | Anxiety | Worsening of Anxiety | 05MAR2021 (53) | | ONGOING | | | 2 |
| 2 | SKIN | Urticaria | hives forehead | 12JAN2021 (1) | 11:29 | 12JAN2021 (1) | | 1 | 1 |

| Adverse Events | | | | | | | |
|----------------|-------------------|-----|----------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | TC | N | Yes | NOT RELATED/OTHER: medication dosage adjustment | 2 | 30 | N |
| 2 | N | N | Resolved (12JAN2021) | Study Treatment | 1 | 1 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Page 16 of 40

Reason(s) for Narrative: Adverse Events With Numerical Imbalance Between Vaccine Groups

Unique Subject ID: C4591001 1044 10441373; Country: USA

Vaccine Group (as Administered): Placebo

Date of First Dose: 12JAN2021; Date of Last Dose: 04FEB2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 12JAN2021 | |
| Completed | VACCINATION | 09MAR2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1077 10771278; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 23DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2007 | 13 | White | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 165.1 cm | 47.09 kg | 17.2 kg/m2 | 04DEC2020 (1) |

| Medical History |
|--------------------|
| No Medical History |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 04DEC2020 (1) | 09:45 |
| 2 | BNT162b2 | 23DEC2020 (20) | 10:09 |

Compound: PF-07302048; Protocol: C4591001

Page 18 of 40

Reason(s) for Narrative: Psychiatric Disorders

Unique Subject ID: C4591001 1077 10771278; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 04DEC2020; Date of Last Dose: 23DEC2020

| Adverse Events | | | | | | | |
|----------------|------------|-------------------------|-------------------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | GASTR | Diarrhoea | DIARRHEA | 23DEC2020 (20) | 12:30 | 24DEC2020 (21) | 12:01 |
| 2 | PSYCH | Disorientation | DISORIENTATION | 23DEC2020 (20) | 19:01 | 23DEC2020 (20) | 20:00 |
| 3 | GENRL | Fatigue | FATIGUE | 23DEC2020 (20) | 14:00 | 24DEC2020 (21) | |
| 4 | GENRL | Injection site pain | RIGHT ARM INJECTION SITE PAIN | 23DEC2020 (20) | 12:00 | 24DEC2020 (21) | 22:00 |
| 5 | GENRL | Injection site swelling | INJECTION SITE SWELLING | 23DEC2020 (20) | 12:00 | 24DEC2020 (21) | 21:00 |
| 6 | GENRL | Pyrexia | FEVER | 23DEC2020 (20) | 19:01 | 24DEC2020 (21) | 12:00 |
| 7 | GASTR | Vomiting | VOMITING | 23DEC2020 (20) | 20:00 | 23DEC2020 (20) | 21:00 |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|----------------------|-----------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | 2 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 2 | 1 | 2 | N | N | Resolved (23DEC2020) | Study Treatment | 2 | 1 | N |
| 3 | 2 | 2 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 4 | 2 | 1 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 5 | 2 | 2 | N | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 6 | 2 | 3 | TC | N | Resolved (24DEC2020) | Study Treatment | 2 | 1 | N |
| 7 | 1 | 1 | N | N | Resolved (23DEC2020) | Study Treatment | 2 | 1 | N |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1077 10771278; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 04DEC2020; Date of Last Dose: 23DEC2020

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 04DEC2020 | |
| Completed | VACCINATION | 22JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1123 11231442; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 04JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2008 | 12 | White | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 164 cm | 86.5 kg | 32.2 kg/m2 | 09DEC2020 (1) |

| Medical History | | | |
|------------------------|---------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Chronic strep throat | Pharyngitis streptococcal | 2016 | Past |
| Adenoidectomy | Adenoidectomy | 2017 | Past |
| Intermittent headaches | Headache | 2017 | Present |
| Obesity | Obesity | 2017 | Present |
| Tonsillectomy | Tonsillectomy | 2017 | Past |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1123 11231442; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 04JAN2021

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 09DEC2020 (1) | 12:33 |
| 2 | Placebo | 04JAN2021 (27) | 13:48 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Depression | Depression | 23DEC2020 (15) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|----------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 2 | TC | N | Yes | NOT RELATED/OTHER: unknown | 1 | 15 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1123 11231442; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 04JAN2021

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 09DEC2020 | |
| Completed | VACCINATION | 01FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 23 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 162.5 cm | 50.7 kg | 19.2 kg/m2 | 28DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Seasonal allergies | Seasonal allergy | 2008 | Present |
| Attention deficit hyperactive disorder | Attention deficit hyperactivity disorder | 2013 | Present |
| Migraines | Migraine | 2015 | Present |
| Anxiety | Anxiety | OCT2018 | Present |
| Depression | Depression | OCT2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 24 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 28DEC2020 (1) | 16:52 |
| 2 | BNT162b2 | 18JAN2021 (22) | 11:50 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Worsening of Depression | 19JAN2021 (23) | | 23JAN2021 (27) | | 5 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|----------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | TC | Y | Resolved (23JAN2021) | NOT RELATED/OTHER: unknown | 2 | 2 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 28DEC2020 | |
| Completed | VACCINATION | 16FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1147 11471262; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 12DEC2020; Date of Last Dose: 04JAN2021

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 165.2 cm | 65.15 kg | 23.9 kg/m2 | 12DEC2020 (1) |

| Medical History | | | |
|------------------------------|------------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Generalized anxiety disorder | Generalised anxiety disorder | 2020 | Present |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 12DEC2020 (1) | 09:09 |
| 2 | BNT162b2 | 04JAN2021 (24) | 10:25 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1147 11471262; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 12DEC2020; Date of Last Dose: 04JAN2021

| Adverse Events | | | | | | | | |
|----------------|------------|------------------------------|--|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Generalised anxiety disorder | Generalized anxiety disorder (worsening) | 25JAN2021 (45) | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 1 | TC | N | Yes | NOT RELATED/OTHER: Worsening condition | 2 | 22 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines | | |
|-------------------|-------------------------|------------|
| Investigator Text | WHO Drug Preferred Term | Start Date |
| Influenza vaccine | INFLUENZA VACCINE | 23NOV2020 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1147 11471262; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 12DEC2020; Date of Last Dose: 04JAN2021

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 01DEC2020 | |
| Completed | VACCINATION | 06FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1150 11501193; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 10DEC2020; Date of Last Dose: 31DEC2020

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 163.83 cm | 50.27 kg | 18.7 kg/m2 | 10DEC2020 (1) |

| Medical History | | | |
|----------------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Sun butter Allergy- Food Allergy | Food allergy | 2016 | Present |
| Sesame Seed Allergy | Food allergy | 2016 | Present |
| Seasonal Allergies | Seasonal allergy | 2016 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1150 11501193; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 10DEC2020; Date of Last Dose: 31DEC2020

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 10DEC2020 (1) | 15:02 |
| 2 | Placebo | 31DEC2020 (22) | 10:25 |

| Adverse Events | | | | | | | |
|----------------|------------|--|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Attention deficit hyperactivity disorder | ADHD | DEC2020 () | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|-------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | N | N | Yes | NOT RELATED/OTHER: ADHD | | | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1150 11501193; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 10DEC2020; Date of Last Dose: 31DEC2020

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 10DEC2020 | |
| Completed | VACCINATION | 01FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1152 11521654; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 29DEC2020

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 160.66 cm | 80.45 kg | 31.1 kg/m2 | 09DEC2020 (1) |

| Medical History | | | |
|--|---|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| DEPRESSION | Depression | 2010 | Present |
| foreign body right ear lobe | Foreign body in ear | 2011 | Past |
| surgical removal foreign object right ear lobe | Removal of foreign body from external ear | 2011 | Past |
| astigmatism | Astigmatism | 2015 | Present |
| seasonal allergies | Seasonal allergy | 2015 | Present |
| frequent headaches | Headache | 2018 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1152 11521654; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 29DEC2020

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 09DEC2020 (1) | 11:45 |
| 2 | Placebo | 29DEC2020 (21) | 10:09 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|---------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Worsened Depression | 26DEC2020 (18) | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | TC | N | Yes | NOT RELATED/OTHER: Pre-existing condition | 1 | 18 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1152 11521654; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 09DEC2020; Date of Last Dose: 29DEC2020

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 09DEC2020 | |
| Completed | VACCINATION | 27JAN2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 35 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1270 12701222; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 18DEC2020; Date of Last Dose: 08JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 167.6 cm | 60.6 kg | 21.6 kg/m2 | 18DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention Deficit Hyperactivity Disorder | Attention deficit hyperactivity disorder | JAN2015 | Present |
| Right knee pain | Arthralgia | 19JUN2020 | Present |
| Right Forearm Pain | Pain in extremity | 19JUN2020 | Present |
| Anxiety | Anxiety | 31AUG2020 | Present |
| Depression | Depression | 08DEC2020 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 36 of 40

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1270 12701222; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 18DEC2020; Date of Last Dose: 08JAN2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 18DEC2020 (1) | 16:30 |
| 2 | BNT162b2 | 08JAN2021 (22) | 14:18 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Suicidal ideation | SUICIDAL IDEATION | 16FEB2021 (61) | 10:17 | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TCN | Y | Yes | NOT RELATED/OTHER: PSYCHOSOCIAL ISSUES | 2 | 40 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1270 12701222; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 18DEC2020; Date of Last Dose: 08JAN2021

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 18DEC2020 | |
| Completed | VACCINATION | 05FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1270 12701236; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 06JAN2021; Date of Last Dose: 25JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 164.8 cm | 71.6 kg | 26.4 kg/m2 | 06JAN2021 (1) |

| Medical History | | | |
|-----------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| LEARNING DIFFICULTIES | Learning disorder | 08AUG2017 | Present |

| Study Vaccination(s) | | | |
|----------------------|---------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 06JAN2021 (1) | 15:18 |
| 2 | Placebo | 25JAN2021 (20) | 14:29 |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1270 12701236; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 06JAN2021; Date of Last Dose: 25JAN2021

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | PSYCH | Anxiety | Anxiety | 11JAN2021 (6) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|--------------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 1 | N | N | Yes | NOT RELATED/OTHER: Social Situations | 1 | 6 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Psychiatric Disorders
Unique Subject ID: C4591001 1270 12701236; Country: USA
Vaccine Group (as Administered): Placebo
Date of First Dose: 06JAN2021; Date of Last Dose: 25JAN2021

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 06JAN2021 | |
| Completed | VACCINATION | 23FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 1 of 13

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

| Demography | | | | |
|---------------|---------------------------|---------------------------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2007 | 13 | Black or African American | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 172.72 cm | 67.27 kg | 22.5 kg/m2 | 16DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention Deficit Hyperactivity Disorder | Attention deficit hyperactivity disorder | 2010 | Present |
| Separation Anxiety Disorder | Separation anxiety disorder | 2010 | Present |
| Disruptive Mood Dysregulation Disorder | Disruptive mood dysregulation disorder | 2012 | Present |
| Asthma | Asthma | 2013 | Present |
| Anxiety | Anxiety | 2014 | Present |
| Depression | Depression | 2014 | Present |
| Recurring Insomnia | Insomnia | 2014 | Present |
| Recurring Nightmares | Nightmare | 2015 | Present |
| Post Traumatic Stress Disorder | Post-traumatic stress disorder | 06NOV2015 | Present |
| Aggressive Behaviors | Aggression | 2017 | Past |

PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: dm, vs, mh, ex, ae, cm, ds Output

File: ./nda2_unblinded/C4591001_EUA_Narrative_Safety/profile Date of Generation: 01APR2021 (10:32)

FDA-CBER-2022-5812-0516422

090177e196ee84a6\Final\Final On: 02-May-2021 02:39 (GMT)

Compound: PF-07302048; Protocol: C4591001

Page 2 of 13

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

=====

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 16DEC2020 (1) | 12:07 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Anxiety | Worsening of anxiety | 23DEC2020 (8) | | 18JAN2021 (34) | | 27 |
| 2 | INJ&P | Contusion | Contusion left elbow | 05FEB2021 (52) | | ONGOING | | |
| 3 | PSYCH | Depression | Worsening of Depression | 23DEC2020 (8) | | 18JAN2021 (34) | | 27 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|--------------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC/TCN/P | Y | Resolved (18JAN2021) | NOT RELATED/OTHER: Stress | 1 | 8 | Y |
| 2 | 1 | N | N | Yes | NOT RELATED/OTHER: Fall on ice | 1 | 52 | N |
| 3 | 3 | TC/TCN/P | Y | Resolved (18JAN2021) | NOT RELATED/OTHER: Stress | 1 | 8 | Y |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Safety-Related Subject Withdrawal
Unique Subject ID: C4591001 1006 10061272; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

=====

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 16DEC2020 | |
| Withdrawn | VACCINATION | 06JAN2021 | ADVERSE EVENT |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 4 of 13

Reason(s) for Narrative: Safety-Related Subject Withdrawal

Unique Subject ID: C4591001 1006 10061272; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 16DEC2020; Date of Last Dose: 16DEC2020

Narrative Comment

Subject C4591001 1006 10061272, a 13-year-old black or African American female with a pertinent medical history of attention deficit hyperactivity disorder and separation anxiety disorder (both since 2010); disruptive mood dysregulation disorder (since 2012); anxiety, depression, and recurring insomnia (all since 2014); recurring nightmares (since 2015); posttraumatic stress disorder (since 06 Nov 2015); and aggression (in 2017 with 4 days' hospitalization), received Dose 1 on 16 Dec 2020. The family medical history was pertinent for posttraumatic stress disorder, borderline personality disorder (b) (6), and drug addiction (b) (6). The subject experienced worsening of anxiety and worsening of depression on 23 Dec 2020, 7 days after receiving Dose 1.

Concomitant medications included salbutamol and fluticasone propionate (both since 2013) and montelukast sodium (from 2013 to 30 Dec 2020) for asthma; and duloxetine hydrochloride (from 2019 to 30 Dec 2020) and citalopram hydrobromide (from Oct 2020 to 30 Dec 2020), both for depression.

The subject, with an ongoing medical history of anxiety and depression, which were stable at Visit 1, experienced worsening of anxiety and depression after Visit 1 on 23 Dec 2020 (Day 8) and was hospitalized for 14 days. During hospitalization, the subject was seen by a physician and was treated with aripiprazole 1 mg and venlafaxine 150 mg per day (starting on 30 Dec 2020) and the physician recommended admission to an inpatient residential treatment/psychiatric facility. On 05 Jan 2021 (Day 21), the subject was admitted to an inpatient residential treatment/psychiatric facility for medical management and stabilization. The subject was not tested for COVID-19. During a scheduled visit, the subject and her guardian stated that the subject's mental health had stabilized, and she was treated with trazodone 50 mg every night (from 06 Jan 2021) for her history of recurring insomnia. On 18 Jan 2021 (Day 34), the worsening of anxiety and worsening of depression resolved and the subject was discharged from the hospital on the same day.

The subject was discontinued from the study intervention on 06 Jan 2021 because of the worsening of anxiety and depression and remains in the study to be evaluated for safety, immunogenicity, and efficacy.

In the opinion of the investigator, there was no reasonable possibility that the worsening of anxiety and worsening of depression were related to the study intervention, concomitant medications, or clinical trial procedures, but rather they were related to stress. Pfizer did not assess the worsening of anxiety and worsening of depression as related to the study intervention, concomitant medications, or clinical trial procedures.

Compound: PF-07302048; Protocol: C4591001

Page 5 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2005 | 15 | Asian | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 177.7 cm | 65.5 kg | 20.7 kg/m2 | 11JAN2021 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| asthma | Asthma | 2006 | Past |
| glasses user | Corrective lens user | 2012 | Present |
| seasonal allergic rhinitis | Seasonal allergy | 2016 | Present |
| anxiety | Anxiety | 2018 | Present |
| attention deficit hyperactivity disorder | Attention deficit hyperactivity disorder | 2018 | Present |
| Depression | Depression | 2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 6 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 11JAN2021 (1) | 12:50 |
| 2 | BNT162b2 | 01FEB2021 (22) | 08:31 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Depression Exacerbation | 26JAN2021 (16) | | 30JAN2021 (20) | | 5 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|---------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC/TCN | Y | Resolved (30JAN2021) | NOT RELATED/OTHER: Stress | 1 | 16 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Page 7 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1039 10391326; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 11JAN2021; Date of Last Dose: 01FEB2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 11JAN2021 | |
| Completed | VACCINATION | 04MAR2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 8 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 162.5 cm | 50.7 kg | 19.2 kg/m2 | 28DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Seasonal allergies | Seasonal allergy | 2008 | Present |
| Attention deficit hyperactive disorder | Attention deficit hyperactivity disorder | 2013 | Present |
| Migraines | Migraine | 2015 | Present |
| Anxiety | Anxiety | OCT2018 | Present |
| Depression | Depression | OCT2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 9 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 28DEC2020 (1) | 16:52 |
| 2 | BNT162b2 | 18JAN2021 (22) | 11:50 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Depression | Worsening of Depression | 19JAN2021 (23) | | 23JAN2021 (27) | | 5 |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|----------------------|----------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 2 | TC | Y | Resolved (23JAN2021) | NOT RELATED/OTHER: unknown | 2 | 2 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1123 11231507; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 28DEC2020; Date of Last Dose: 18JAN2021

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 28DEC2020 | |
| Completed | VACCINATION | 16FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 11 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1270 12701222; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 18DEC2020; Date of Last Dose: 08JAN2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2006 | 14 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 167.6 cm | 60.6 kg | 21.6 kg/m2 | 18DEC2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Attention Deficit Hyperactivity Disorder | Attention deficit hyperactivity disorder | JAN2015 | Present |
| Right knee pain | Arthralgia | 19JUN2020 | Present |
| Right Forearm Pain | Pain in extremity | 19JUN2020 | Present |
| Anxiety | Anxiety | 31AUG2020 | Present |
| Depression | Depression | 08DEC2020 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 12 of 13

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1270 12701222; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 18DEC2020; Date of Last Dose: 08JAN2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 18DEC2020 (1) | 16:30 |
| 2 | BNT162b2 | 08JAN2021 (22) | 14:18 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|-------------------|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | PSYCH | Suicidal ideation | SUICIDAL IDEATION | 16FEB2021 (61) | 10:17 | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TCN | Y | Yes | NOT RELATED/OTHER: PSYCHOSOCIAL ISSUES | 2 | 40 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1270 12701222; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 18DEC2020; Date of Last Dose: 08JAN2021

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 18DEC2020 | |
| Completed | VACCINATION | 05FEB2021 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 1 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1003 10031207; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 14AUG2020; Date of Last Dose: 04SEP2020

=====

| Demography | | | | |
|---------------|---------------------------|---------------------------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1967 | 53 | Black or African American | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|-----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 180.34 cm | 123.18 kg | 37.8 kg/m2 | 14AUG2020 (1) |

| Medical History | | | |
|----------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| left hip replacement | Hip arthroplasty | 2018 | Present |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 14AUG2020 (1) | 12:50 |
| 2 | BNT162b2 | 04SEP2020 (22) | 11:42 |

Compound: PF-07302048; Protocol: C4591001

Page 2 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1003 10031207; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 14AUG2020; Date of Last Dose: 04SEP2020

| Adverse Events | | | | | | | | | |
|----------------|------------|-----------------------|-------------------------------|------------------------|------------|-----------------------|-----------|-----------------|----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade |
| 1 | VASC | Deep vein thrombosis | bilateral lower extremity DVT | 27DEC2020 (136) | | 12FEB2021 (183) | | 48 | 3 |
| 2 | CONG | Protein S deficiency | S protein deficiency | 28DEC2020 (137) | | ONGOING | | | 2 |
| 3 | RESP | Pulmonary embolism | pulmonary embolism | 28DEC2020 (137) | | 11JAN2021 (151) | | 15 | 3 |

| Adverse Events | | | | | | | |
|----------------|-------------------|-----|----------------------|---|--------------------------|-------------------------------------|-----------------|
| AE Number | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | TC | Y | Resolved (12FEB2021) | NOT RELATED/OTHER: unknown | 2 | 115 | Y |
| 2 | TC | N | Yes | NOT RELATED/OTHER: protein S deficiency | 2 | 116 | N |
| 3 | TC | Y | Resolved (11JAN2021) | NOT RELATED/OTHER: DVT | 2 | 116 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1003 10031207; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 14AUG2020; Date of Last Dose: 04SEP2020

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 14AUG2020 | |
| Completed | VACCINATION | 02OCT2020 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 4 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1013 10131089; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 06AUG2020; Date of Last Dose: 25FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1991 | 29 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 153.4 cm | 52.5 kg | 22.3 kg/m2 | 06AUG2020 (1) |

| Medical History | | | |
|-------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| HISTORY OF SEIZURES | Seizure | 2004 | Past |
| LEFT TORN LABRUM | Cartilage injury | SEP2009 | Past |
| LEFT TORN LABRUM REPAIR | Chondroplasty | 2011 | Past |
| ENVIRONMENTAL ALLERGIES | Hypersensitivity | FEB2020 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 5 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1013 10131089; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 06AUG2020; Date of Last Dose: 25FEB2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 06AUG2020 (1) | 11:25 |
| 2 | Placebo | 27AUG2020 (22) | 13:30 |
| 3 | BNT162b2 | 02FEB2021 (181) | 14:45 |
| 4 | BNT162b2 | 25FEB2021 (204) | 14:15 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|-------------------------------|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | VASC | Deep vein thrombosis | LEFT ARM DEEP VEIN THROMBOSIS | 20DEC2020 (137) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|---------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 3 | TC | Y | Yes | NOT RELATED/OTHER: UNKOWN | 2 | 116 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1013 10131089; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 06AUG2020; Date of Last Dose: 25FEB2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 06AUG2020 | |
| Completed | VACCINATION | 24SEP2020 | |
| Completed | REPEAT SCREENING 1 | 02FEB2021 | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Deep Vein Thrombosis
Unique Subject ID: C4591001 1013 10131207; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 17AUG2020; Date of Last Dose: 09SEP2020

=====

Page 7 of 24

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1967 | 52 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|---------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 163 cm | 79.9 kg | 30.1 kg/m2 | 17AUG2020 (1) |

| Medical History | | | |
|--|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| left knee arthroscopy | Arthroscopy | 08JUN1986 | Past |
| right knee arthroscopy | Arthroscopy | 14SEP1994 | Past |
| Anterior Cervical Discectomy and Fusion - cervical | Spinal fusion surgery | 03DEC1998 | Past |
| POSTMENOPAUSAL | Postmenopause | 01JAN2019 | Present |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Deep Vein Thrombosis
Unique Subject ID: C4591001 1013 10131207; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 17AUG2020; Date of Last Dose: 09SEP2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 17AUG2020 (1) | 13:25 |
| 2 | BNT162b2 | 09SEP2020 (24) | 15:15 |

| Adverse Events | | | | | | | | | |
|----------------|------------|-----------------------|--|------------------------|------------|-----------------------|-----------|-----------------|----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade |
| 1 | GENRL | Chills | CHILLS | 10SEP2020 (25) | 13:00 | 10SEP2020 (25) | 18:00 | 1 | 2 |
| 2 | VASC | Deep vein thrombosis | DEEP VEIN THROMBOSIS RIGHT POPTIAL VEIN | 23SEP2020 (38) | 16:30 | 28SEP2020 (43) | 12:00 | 6 | 3 |
| 3 | GENRL | Fatigue | FATIGUE | 10SEP2020 (25) | 09:00 | 12SEP2020 (27) | 20:00 | 3 | 2 |
| 4 | GENRL | Pain | BODY ACHES | 10SEP2020 (25) | 09:00 | 11SEP2020 (26) | 12:00 | 2 | 2 |
| 5 | GENRL | Pain | body aches | 14SEP2020 (29) | 08:00 | 15SEP2020 (30) | 08:00 | 2 | 3 |
| 6 | GENRL | Pyrexia | FEVER | 10SEP2020 (25) | 17:00 | 17SEP2020 (32) | 23:00 | 8 | 2 |

| Adverse Events | | | | | | | |
|----------------|-------------------|-----|----------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | N | N | Resolved (10SEP2020) | Study Treatment | 2 | 2 | N |
| 2 | TC | N | Resolved (28SEP2020) | NOT RELATED/OTHER: AIRPLANE TRIP/HRT THERAPY | 2 | 15 | N |
| 3 | N | N | Resolved (12SEP2020) | Study Treatment | 2 | 2 | N |
| 4 | TC | N | Resolved (11SEP2020) | Study Treatment | 2 | 2 | N |
| 5 | N | N | Resolved (15SEP2020) | Study Treatment | 2 | 6 | N |
| 6 | TC | N | Resolved (17SEP2020) | Study Treatment | 2 | 2 | N |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Deep Vein Thrombosis
Unique Subject ID: C4591001 1013 10131207; Country: USA
Vaccine Group (as Administered): BNT162b2 (30 µg)
Date of First Dose: 17AUG2020; Date of Last Dose: 09SEP2020

=====

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 17AUG2020 | |
| Completed | VACCINATION | 07OCT2020 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 10 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1013 10131653; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 07OCT2020; Date of Last Dose: 27OCT2020

| Demography | | | | |
|---------------|---------------------------|---------------------------|-----------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 2003 | 16 | Black or African American | Hispanic/Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 155 cm | 102.7 kg | 42.7 kg/m2 | 07OCT2020 (1) |

| Medical History | | | |
|--|--|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| CHARCOT MARIE TOOTH | Hereditary motor and sensory neuropathy | 2005 | Present |
| ASTHMA | Asthma | 2008 | Present |
| ATTENTION DEFICIT HYPERACTIVITY DISORDER | Attention deficit hyperactivity disorder | 2008 | Present |
| ACHILLES TENDON RIGHT AND LEFT RELEASE | Tenoplasty | 2011 | Past |
| ACHILLES TENDON RIGHT AND LEFT RELEASE | Tenoplasty | 2013 | Past |
| OBESITY | Obesity | 2019 | Present |
| ANKLE FRACTURE RIGHT | Ankle fracture | 11SEP2020 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 11 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1013 10131653; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 07OCT2020; Date of Last Dose: 27OCT2020

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 07OCT2020 (1) | 12:09 |
| 2 | BNT162b2 | 27OCT2020 (21) | 14:25 |

| Adverse Events | | | | | | | |
|----------------|------------|-----------------------|---|------------------------|------------|-----------------------|-----------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time |
| 1 | VASC | Deep vein thrombosis | RIGHT LOWER EXTREMITY DEEP VEIN THROMBOSIS | 15NOV2020 (40) | | ONGOING | |

| Adverse Events | | | | | | | | | |
|----------------|-----------------|----------------|-------------------|-----|-------------------|-----------------------------|--------------------------|-------------------------------------|-----------------|
| AE Number | Duration (Days) | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | | 3 | TC | Y | Yes | NOT RELATED/OTHER: FRACTURE | 2 | 20 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1013 10131653; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 07OCT2020; Date of Last Dose: 27OCT2020

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 07OCT2020 | |
| Completed | VACCINATION | 24NOV2020 | |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 13 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1018 10181090; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 06AUG2020; Date of Last Dose: 10FEB2021

| Demography | | | | |
|---------------|---------------------------|-------|-----------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1989 | 31 | White | Hispanic/Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 180.34 cm | 80.45 kg | 24.7 kg/m2 | 06AUG2020 (1) |

| Medical History | | | |
|-------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| broken right lower jaw | Jaw fracture | 2008 | Past |
| right lower jaw surgery | Jaw operation | 2008 | Past |
| Hair Loss | Alopecia | 2014 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 14 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1018 10181090; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 06AUG2020; Date of Last Dose: 10FEB2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 06AUG2020 (1) | 12:29 |
| 2 | Placebo | 27AUG2020 (22) | 09:20 |
| 3 | BNT162b2 | 20JAN2021 (168) | 14:47 |
| 4 | BNT162b2 | 10FEB2021 (189) | 16:01 |

| Adverse Events | | | | | | | | |
|----------------|------------|-----------------------|--|------------------------|------------|-----------------------|-----------|-----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) |
| 1 | VASC | Deep vein thrombosis | Deep Vein Thrombosis, left leg | 27NOV2020 (114) | | ONGOING | | |
| 2 | RESP | Pulmonary embolism | Pulmonary Embolism, bilateral, segmental and sub segmental | 14DEC2020 (131) | | ONGOING | | |

| Adverse Events | | | | | | | | |
|----------------|----------------|-------------------|-----|-------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Toxicity Grade | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | 3 | TC | Y | Yes | NOT RELATED/OTHER: Trauma, sports related | 2 | 93 | Y |
| 2 | 4 | TC | Y | Yes | NOT RELATED/OTHER: DVT of left leg, FH, marker | 2 | 110 | Y |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1018 10181090; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 06AUG2020; Date of Last Dose: 10FEB2021

=====

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 06AUG2020 | |
| Completed | VACCINATION | 28SEP2020 | |
| Completed | REPEAT SCREENING 1 | 20JAN2021 | |
| Completed | OPEN LABEL TREATMENT | 11MAR2021 | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Deep Vein Thrombosis
Unique Subject ID: C4591001 1125 11251053; Country: USA
Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)
Date of First Dose: 18AUG2020; Date of Last Dose: 08MAR2021

=====

| Demography | | | | |
|---------------|---------------------------|-------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1967 | 53 | White | Non-Hispanic/non-Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|-----------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 172.72 cm | 112.27 kg | 37.6 kg/m2 | 18AUG2020 (1) |

| Medical History | | | |
|------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Depression | Depression | 2002 | Present |
| Cholecystectomy | Cholecystectomy | 2008 | Past |
| Cholecystitis | Cholecystitis | 2008 | Past |
| Allergy to Clindamycin | Drug hypersensitivity | 2010 | Present |
| Rash on chest | Rash | 2015 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 17 of 24

Reason(s) for Narrative: Deep Vein Thrombosis

Unique Subject ID: C4591001 1125 11251053; Country: USA

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 18AUG2020; Date of Last Dose: 08MAR2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 18AUG2020 (1) | 10:03 |
| 2 | Placebo | 09SEP2020 (23) | 12:27 |
| 3 | BNT162b2 | 15FEB2021 (182) | 11:21 |
| 4 | BNT162b2 | 08MAR2021 (203) | 13:26 |

| Adverse Events | | | | | | | | | |
|----------------|------------|-------------------------|----------------------------------|------------------------|------------|-----------------------|-----------|-----------------|----------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade |
| 1 | VASC | Deep vein thrombosis | Deep vein thrombosis of left leg | 03DEC2020 (108) | | 03DEC2020 (108) | | 1 | 1 |
| 2 | BLOOD | Iron deficiency anaemia | Iron deficiency anemia | 03DEC2020 (108) | | 15FEB2021 (182) | | 75 | 1 |

| Adverse Events | | | | | | | |
|----------------|-------------------|-----|----------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | Action to Subject | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | TC | N | Resolved (03DEC2020) | NOT RELATED/OTHER: Metabolic/hematologic | 2 | 86 | N |
| 2 | TC | N | Resolved (15FEB2021) | NOT RELATED/OTHER: Metabolic/hematologic | 2 | 86 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

Compound: PF-07302048; Protocol: C4591001
Reason(s) for Narrative: Deep Vein Thrombosis
Unique Subject ID: C4591001 1125 11251053; Country: USA
Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)
Date of First Dose: 18AUG2020; Date of Last Dose: 08MAR2021

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 18AUG2020 | |
| Completed | VACCINATION | 07OCT2020 | |
| Completed | REPEAT SCREENING 1 | 15FEB2021 | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 19 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1156 11561006; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 20AUG2020; Date of Last Dose: 20AUG2020

=====

| Demography | | | | |
|---------------|---------------------------|---------------------------|-------------------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1974 | 45 | Black or African American | Non-Hispanic/non-Latino | M |

| Vital Signs - Baseline | | | |
|------------------------|--------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 167.2 cm | 74 kg | 26.5 kg/m2 | 20AUG2020 (1) |

| Medical History | | | |
|-------------------|--------------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Type 1 Diabetes | Type 1 diabetes mellitus | AUG2014 | Present |

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | BNT162b2 | 20AUG2020 (1) | 11:44 |

Compound: PF-07302048; Protocol: C4591001

Page 20 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1156 11561006; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 20AUG2020; Date of Last Dose: 20AUG2020

| Adverse Events | | | | | | | | | | |
|----------------|------------|---------------------------|--------------------------|------------------------|------------|-----------------------|-----------|-----------------|----------------|-------------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade | Action to Subject |
| 1 | VASC | Deep vein thrombosis | DEEP VEIN THROMBOSIS | 31AUG2020 (12) | | 09SEP2020 (21) | | 10 | 3 | TC |
| 2 | MUSC | Musculoskeletal stiffness | right shoulder stiffness | 05SEP2020 (17) | | 07SEP2020 (19) | | 3 | 1 | TCN |
| 3 | RESP | Pulmonary embolism | PULMONARY EMBOLISM | 31AUG2020 (12) | | 02SEP2020 (14) | | 3 | 3 | TC |

| Adverse Events | | | | | | |
|----------------|-----|----------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | Y | Resolved (09SEP2020) | NOT RELATED/OTHER: MEDICAL HISTORY - TYPE 1 DIABETES | 1 | 12 | Y |
| 2 | N | Resolved (07SEP2020) | NOT RELATED/OTHER: unknown new medical condition | 1 | 17 | N |
| 3 | N | Resolved (02SEP2020) | NOT RELATED/OTHER: DEEP VEIN THROMBOSIS | 1 | 12 | N |

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

Compound: PF-07302048; Protocol: C4591001

Page 21 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1156 11561006; Country: USA

Vaccine Group (as Administered): BNT162b2 (30 µg)

Date of First Dose: 20AUG2020; Date of Last Dose: 20AUG2020

=====

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|--------------------------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 20AUG2020 | |
| Withdrawn | VACCINATION | 08SEP2020 | NO LONGER MEETS ELIGIBILITY CRITERIA |
| | REPEAT SCREENING 1 | | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |

Compound: PF-07302048; Protocol: C4591001

Page 22 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1226 12262052; Country: Brazil

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 03OCT2020; Date of Last Dose: 05MAR2021

=====

| Demography | | | | |
|---------------|---------------------------|-------|-----------------|-----|
| Date of Birth | Age at Enrollment (Years) | Race | Ethnicity | Sex |
| (b) (6) 1969 | 51 | White | Hispanic/Latino | F |

| Vital Signs - Baseline | | | |
|------------------------|--------|------------|----------------------------|
| Height | Weight | BMI | Date Collected (Study Day) |
| 159.3 cm | 103 kg | 40.6 kg/m2 | 03OCT2020 (1) |

| Medical History | | | |
|---------------------------|-----------------------|------------|----------------|
| Investigator Text | MedDRA Preferred Term | Start Date | Disease Status |
| Pulmonary thromboembolism | Pulmonary embolism | 1999 | Past |
| Obesity | Obesity | 2010 | Present |
| Gastritis | Gastritis | 2018 | Present |

Compound: PF-07302048; Protocol: C4591001

Page 23 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1226 12262052; Country: Brazil

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 03OCT2020; Date of Last Dose: 05MAR2021

| Study Vaccination(s) | | | |
|----------------------|----------|------------------------------|---------------------|
| Vaccination Number | Vaccine | Vaccination Date (Study Day) | Time of Vaccination |
| 1 | Placebo | 03OCT2020 (1) | 12:05 |
| 2 | Placebo | 26OCT2020 (24) | 11:49 |
| 3 | BNT162b2 | 13FEB2021 (134) | 13:00 |
| 4 | BNT162b2 | 05MAR2021 (154) | 11:25 |

| Adverse Events | | | | | | | | | | |
|----------------|------------|------------------------|--|------------------------|------------|-----------------------|-----------|-----------------|----------------|-------------------|
| AE Number | MedDRA SOC | MedDRA Preferred Term | Investigator Text | Start Date (Study Day) | Start Time | Stop Date (Study Day) | Stop Time | Duration (Days) | Toxicity Grade | Action to Subject |
| 1 | VASC | Deep vein thrombosis | Deep vein thrombosis in right lower limb | 05JAN2021 (95) | | 13JAN2021 (103) | | 9 | 2 | TC/TCN |
| 2 | VASC | Venous thrombosis limb | Vein thrombosis in right lower limb | 14JAN2021 (104) | | 22FEB2021 (143) | | 40 | 2 | TC |

| Adverse Events | | | | | | |
|----------------|-----|----------------------|--|--------------------------|-------------------------------------|-----------------|
| AE Number | SAE | AE Still Present? | AE Related To: | Prior Vaccination Number | Relative Day From Prior Vaccination | Narrative Event |
| 1 | Y | Resolved (13JAN2021) | NOT RELATED/OTHER: reduced mobility (due to quarantine period) | 2 | 72 | Y |
| 2 | N | Resolved (22FEB2021) | NOT RELATED/OTHER: Unknown | 2 | 81 | N |

Compound: PF-07302048; Protocol: C4591001

Page 24 of 24

Reason(s) for Narrative: Other SAE

Unique Subject ID: C4591001 1226 12262052; Country: Brazil

Vaccine Group (as Administered): Placebo => BNT162b2 (30 µg)

Date of First Dose: 03OCT2020; Date of Last Dose: 05MAR2021

| Prohibited Concomitant Medications |
|---------------------------------------|
| No Prohibited Concomitant Medications |

| Nonstudy Vaccines |
|----------------------|
| No Nonstudy Vaccines |

| Subject Summary | | | |
|-----------------|----------------------|----------------------------|-----------------------|
| Status | Study Phase | Withdrawal/Completion Date | Reason for Withdrawal |
| Completed | SCREENING | 03OCT2020 | |
| Completed | VACCINATION | 23NOV2020 | |
| Completed | REPEAT SCREENING 1 | 13FEB2021 | |
| | OPEN LABEL TREATMENT | | |
| | FOLLOW-UP | | |